These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

331 related items for PubMed ID: 18553995

  • 1. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry.
    Garbis SD, Tyritzis SI, Roumeliotis T, Zerefos P, Giannopoulou EG, Vlahou A, Kossida S, Diaz J, Vourekas S, Tamvakopoulos C, Pavlakis K, Sanoudou D, Constantinides CA.
    J Proteome Res; 2008 Aug; 7(8):3146-58. PubMed ID: 18553995
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis.
    Pang J, Liu WP, Liu XP, Li LY, Fang YQ, Sun QP, Liu SJ, Li MT, Su ZL, Gao X.
    J Proteome Res; 2010 Jan; 9(1):216-26. PubMed ID: 19894759
    [Abstract] [Full Text] [Related]

  • 5. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers.
    Sardana G, Jung K, Stephan C, Diamandis EP.
    J Proteome Res; 2008 Aug; 7(8):3329-38. PubMed ID: 18578523
    [Abstract] [Full Text] [Related]

  • 6. Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma.
    Alaiya AA, Al-Mohanna M, Aslam M, Shinwari Z, Al-Mansouri L, Al-Rodayan M, Al-Eid M, Ahmad I, Hanash K, Tulbah A, Bin Mahfooz A, Adra C.
    Int J Oncol; 2011 Apr; 38(4):1047-57. PubMed ID: 21305254
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical proteomics: discovery of cancer biomarkers using mass spectrometry and bioinformatics approaches--a prostate cancer perspective.
    Matharoo-Ball B, Ball G, Rees R.
    Vaccine; 2007 Sep 27; 25 Suppl 2():B110-21. PubMed ID: 17916461
    [Abstract] [Full Text] [Related]

  • 9. Absolute quantification of potential cancer markers in clinical tissue homogenates using multiple reaction monitoring on a hybrid triple quadrupole/linear ion trap tandem mass spectrometer.
    DeSouza LV, Romaschin AD, Colgan TJ, Siu KW.
    Anal Chem; 2009 May 01; 81(9):3462-70. PubMed ID: 19323455
    [Abstract] [Full Text] [Related]

  • 10. [P53 expression and its clinical significance in prostatic carcinoma].
    Jiang T, Jiang H, Song XS, Li XC, Li QL.
    Zhonghua Nan Ke Xue; 2005 Jun 01; 11(6):448-51, 454. PubMed ID: 15999492
    [Abstract] [Full Text] [Related]

  • 11. A novel multidimensional protein identification technology approach combining protein size exclusion prefractionation, peptide zwitterion-ion hydrophilic interaction chromatography, and nano-ultraperformance RP chromatography/nESI-MS2 for the in-depth analysis of the serum proteome and phosphoproteome: application to clinical sera derived from humans with benign prostate hyperplasia.
    Garbis SD, Roumeliotis TI, Tyritzis SI, Zorpas KM, Pavlakis K, Constantinides CA.
    Anal Chem; 2011 Feb 01; 83(3):708-18. PubMed ID: 21174401
    [Abstract] [Full Text] [Related]

  • 12. TP53 mutation in prostate needle biopsies--comparison with patients follow-up.
    Ecke TH, Schlechte HH, Hübsch A, Lenk SV, Schiemenz K, Rudolph BD, Miller K.
    Anticancer Res; 2007 Feb 01; 27(6B):4143-8. PubMed ID: 18225585
    [Abstract] [Full Text] [Related]

  • 13. Preliminary studies on the isolation and characterization of predominant prostatic proteins.
    Lombardo ME, Meyer-Siegler K, Hakky SI, Hudson PB.
    Prostate; 1996 Dec 01; 29(6):381-5. PubMed ID: 8977635
    [Abstract] [Full Text] [Related]

  • 14. The role of prostate specific membrane antigen and pepsinogen C tissue expression as an adjunctive method to prostate cancer diagnosis.
    Antunes AA, Leite KR, Sousa-Canavez JM, Camara-Lopes LH, Srougi M.
    J Urol; 2009 Feb 01; 181(2):594-600. PubMed ID: 19084862
    [Abstract] [Full Text] [Related]

  • 15. Urinary CD14 as a potential biomarker for benign prostatic hyperplasia - discovery by combining MALDI-TOF-based biostatistics and ESI-MS/MS-based stable-isotope labeling.
    Cheng HL, Huang HJ, Ou BY, Chow NH, Chen YW, Tzai TS, Wu CJ, Chen SH.
    Proteomics Clin Appl; 2011 Apr 01; 5(3-4):121-32. PubMed ID: 21322116
    [Abstract] [Full Text] [Related]

  • 16. [Differentially expressed genes in prostate cancer and benign prostatic hyperplasia].
    Zhang T, Xu Y, Tang H, Liu M, Ren D, Niu Y.
    Zhonghua Nan Ke Xue; 2004 Dec 01; 10(12):897-9. PubMed ID: 15638016
    [Abstract] [Full Text] [Related]

  • 17. Proteomic analysis of protein expression in human tonsillar cancer: differentially expressed proteins characterize human tonsillar cancer.
    Roblick UJ, Bader FG, Hammarstedt L, Habermann JK, Hellman U, Becker S, Sundmacker A, Gemoll T, Zimmermann K, Auer G, Munck-Wikland E.
    Acta Oncol; 2008 Dec 01; 47(8):1493-501. PubMed ID: 18759147
    [Abstract] [Full Text] [Related]

  • 18. Quantitative fluorescence imaging analysis for cancer biomarker discovery: application to beta-catenin in archived prostate specimens.
    Huang D, Casale GP, Tian J, Wehbi NK, Abrahams NA, Kaleem Z, Smith LM, Johansson SL, Elkahwaji JE, Hemstreet GP.
    Cancer Epidemiol Biomarkers Prev; 2007 Jul 01; 16(7):1371-81. PubMed ID: 17623804
    [Abstract] [Full Text] [Related]

  • 19. Proteomics for the identification of new prostate cancer biomarkers.
    Ornstein DK, Tyson DR.
    Urol Oncol; 2006 Jul 01; 24(3):231-6. PubMed ID: 16678055
    [Abstract] [Full Text] [Related]

  • 20. [Application of iTRAQ in proteomic study of prostate cancer].
    Sun CY, Xia GW, Xu K, Ding Q.
    Zhonghua Nan Ke Xue; 2010 Aug 01; 16(8):741-4. PubMed ID: 21090353
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.